MedDataX Logo

Understanding and Overcoming the Racial/Ethnic Inequalities in COVID-19 Vaccination Acceptance

NCT05238428 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4039

Last updated 2022-05-24

No results posted yet for this study

Summary

With the constant threat of new epidemic waves and the emergence of variants, COVID-19 resilience can only be attained when a sufficient level of immunity is achieved. Yet, in the US and the UK, COVID-19 vaccination campaigns have failed to secure consistent vaccination acceptance in racial/ethnic minority communities. Despite racial/ethnic minorities being more at risk from COVID-19, they are less vaccinated than the White majority. The investigators propose that current vaccination invitation messages are deemed less trustworthy by racial/ethnic minorities than the White majority and that this might partly explain reduced vaccination acceptance. To provide causal evidence of the role of trust and actionable insights, the investigators will experimentally assess the benefits of new invitation messages to receive the COVID-19 booster dose in large, racially/ethnically diverse samples in the US and the UK. Results will evidence how to increase message and source trustworthiness to foster trust and vaccination acceptance across racial/ethnic groups.

Conditions

  • Vaccine Refusal

Interventions

BEHAVIORAL

Trust boost

The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.

Sponsors & Collaborators

  • University of Southern California

    collaborator OTHER

  • Department of Health and Social Care

    collaborator UNKNOWN

  • Kingston University

    collaborator OTHER

  • University of Essex

    lead OTHER

Principal Investigators

  • Marie Juanchich, PhD · University of Essex

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-03
Primary Completion
2022-02-28
Completion
2022-03-05

Countries

  • United Kingdom

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238428 on ClinicalTrials.gov